SCHEMBL3653447

SCHEMBL3653447

O=C(Nc1cncs1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 3/20 0.53
▸ BCAT2 O15382 1/20 0.53
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ TP53 P04637 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ NFKB2 Q00653 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NAMPT P43490 2/20 0.50
▸ KDM4D Q6B0I6 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.50
▸ JAK2 O60674 1/20 0.50
▸ TYK2 P29597 1/20 0.50
▸ GAA P10253 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28954592 0.86 GAA (0.55) CSF1RRAB9ATP53MAPTSMN1; SMN2
SCHEMBL7553959 0.85 AQP4 (0.61) MAPTSMN1; SMN2ALOX15MEN1KMT2A
SCHEMBL12700219 0.82 ALDH1A1 (0.53) CSF1RRAB9AMAPTKDM4DKDM4C
SCHEMBL6984067 0.74 RIPK1 (0.52) BCAT2NPC1RAB9ATP53MAPT
SCHEMBL29074245 0.73 NSUN3 (0.55) CSF1RNPC1RAB9ATP53MAPT
SCHEMBL3559655 0.73 MEN1 (0.60) NPC1RAB9ATP53MAPTNFKB1
SCHEMBL31058213 0.72 — —
SCHEMBL1110180 0.71 MDM4 (0.73) NPC1RAB9ATP53MAPTMEN1
SCHEMBL28777345 0.70 ALDH1A1 (0.58) BCAT2NPC1RAB9AMAPTNAMPT
SCHEMBL1685094 0.70 SMN1; SMN2 (0.59) CSF1RNPC1RAB9ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 — — EP claimed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 — — WO claimed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 — — EP disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
US-20080312206-A1 Chemical Compounds-149 ASTRAZENECA AB (SE) 2008-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312206-A1 Chemical Compounds-149 CSF3R, CSF1R, FLT3 CSF1R 2/4885BCAT2 1692/4885NPC1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback